Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06961084 · ClinicalTrials.gov registry record · Phase 2
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
A Phase 2 study of Thyroid Cancer, sponsored by Thomas Hope.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 1
- Study location
NCT06961084 is a Phase 2 study of Thyroid Cancer that is actively recruiting participants, run by Thomas Hope. The registered enrollment target is 62 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06961084, a Phase 2 study of Thyroid Cancer, is actively recruiting participants, sponsored by Thomas Hope.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 1
- Study location
Study Summary
Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imaging for many decades and use I-123 for staging studies. Iodine 124 (I-124) is a radioisotope of iodine which emits a positron and is imaged using PET (positron emission tomography). This is a single arm prospective trial that evaluates the ability of Iodine-124 (I-124) to detect metastatic thyroid cancer compared to non-interventional, usual care I-123 and I-131 images.
Conditions Studied
Interventions
- DRUG Iodine-124
- PROCEDURE Positron Emission Tomography (PET)/Computerized tomography (CT)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2025-07-14 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06961084
The ClinicalTrials.gov registry entry for NCT06961084 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Thomas Hope, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Iodine-124 is the first listed.
NCT06961084 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06961084 about?
NCT06961084 is a clinical study titled "Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer". Persons diagnosed with thyroid cancer are often treated initially with a thyroidectomy, which is followed by ablation using Iodine-131, a therapy which has been shown to be effective and safe. Imaging of metastatic thyroid cancer has been performed with whole body I-131 and Iodine 123 (I-123) imagin...
What is the current status of trial NCT06961084?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2025-07-14. Estimated completion is 2026-03-31.
What conditions does trial NCT06961084 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT06961084?
The interventions under investigation include: Iodine-124 (DRUG), Positron Emission Tomography (PET)/Computerized tomography (CT) (PROCEDURE).
Who is sponsoring clinical trial NCT06961084?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06961084 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
-
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.